Pediatrix Medical Group, Inc. (MEDNAX, Inc.) — Q2 2017 Form 10-Q
Business context and period: The supplied filing is for MEDNAX, Inc., not an entity named Pediatrix Medical Group, Inc. It covers the quarter and six months ended June 30, 2017; the statements are unaudited. MEDNAX provided physician services across neonatal, anesthesia, maternal-fetal, radiology and pediatric specialties, plus teleradiology and related services.
Financial highlights
| Metric | Q2 2017 | Q2 2016 | Six months 2017 | Six months 2016 |
|---|---|---|---|---|
| Revenue | $842.9 million | $771.8 million | $1,678.5 million | $1,524.4 million |
| Operating income | $121.9 million | $147.8 million | $227.9 million | $272.0 million |
| Operating margin | 14.5% | 19.2% | 13.6% | 17.8% |
| Net income attributable to MEDNAX | $63.7 million | $82.4 million | $118.4 million | $150.3 million |
| Diluted EPS | $0.69 | $0.89 | $1.27 | $1.62 |
| Adjusted EPS (non-GAAP) | $0.85 | $1.03 | $1.60 | $1.90 |
| EBITDA (non-GAAP) | $147.6 million | $168.1 million | $279.3 million | $312.1 million |
- Revenue rose 9.2% in Q2 and 10.1% year to date, but growth was acquisition-driven. Same-unit revenue declined 0.9% in both periods.
- Net cash from operations was $115.8 million for the first half, versus $116.7 million a year earlier. Investing used $139.8 million, including $113.7 million for acquisitions and $21.9 million of capital expenditures; financing provided $8.7 million.
- At June 30, cash and equivalents were $40.4 million; working capital was $207.4 million. Total debt principal was approximately $1.78 billion: $1.03 billion under the credit agreement and $750 million of 5.25% senior notes due 2023. Revolver availability was $839.1 million. The company reported compliance with debt covenants.
- Accounts receivable were $480.4 million, down from $495.3 million at year-end 2016. Days sales outstanding improved to 51.9 from 54.9.
Material changes and management commentary
- Six physician-practice acquisitions were completed in the first half for total consideration of $115.2 million, including MEDNAX’s first radiology practice acquisition. Acquisitions contributed $77.6 million of Q2 revenue growth and $168.4 million of first-half growth; the filing says results include acquired practices only from their respective acquisition dates.
- Despite higher revenue, operating income fell 17.5% in Q2 and 16.2% in the first half. Management attributed margin compression to lower same-unit revenue, higher operating expenses and the varying margins of acquired practices.
- Same-unit revenue weakness reflected increased government healthcare program payor mix and lower patient volumes, particularly in neonatology and other pediatric services. Management noted sequentially favorable shifts toward commercial programs in Q2 and modest managed-care contracting improvements.
- Practice salaries and benefits grew faster than revenue; management expected elevated compensation growth, including for non-physician clinicians, to continue in the near term.
- MEDNAX sold its 75% interest in a consolidated joint venture on March 31, 2017; the resulting gain was not material. It also repurchased 1.0 million shares for $70.2 million in the first half.
Outlook, risks and contingencies
- No specific revenue, earnings or margin guidance was provided. Management said operating cash, cash on hand and credit availability should fund working capital, anticipated acquisitions and capital expenditures, repurchases, and contractual obligations for at least the next 12 months.
- Recent anesthesiology payor-mix shifts prompted review of terms for some prospective acquisitions, creating uncertainty about acquisition timing and potential near-term effects.
- Key risks include further shifts to lower-reimbursing government programs, patient inability to pay and bad debt, healthcare reform uncertainty, reimbursement changes, and rising compensation costs. A 1 percentage-point interest-rate change was estimated to affect annual pretax income by approximately $10.3 million.
- The company faces ordinary-course government audits and medical-malpractice claims, indemnification obligations and self-insured professional-liability exposure. It reported $213.8 million of professional-liability liabilities and cautioned that insurance may not cover all future claims. No accrual was recorded for uncertain future government audit or investigation matters because potential liabilities could not be reasonably estimated.
- Management expected the new lease standard, effective for the company in 2019, to materially increase balance-sheet assets and liabilities, primarily for facility leases. Management did not expect the pending revenue-recognition standard to materially affect the financial statements.
Important facts for investors to verify
- Confirm the issuer identity: the supplied 10-Q names MEDNAX, Inc., while the request names Pediatrix Medical Group, Inc.
- Assess whether acquisition-driven growth can offset continued same-unit revenue declines and whether acquired practices can achieve expected operating improvements.
- Track payor mix, patient volumes, clinician compensation growth and operating-margin trends.
- Review debt levels, credit-agreement covenant headroom, interest-rate exposure and the company’s capacity to fund acquisitions and repurchases.
- Monitor healthcare-policy developments and the adequacy of professional-liability insurance and reserves.